Body habitus alterations in HIV-infected women treated with combined antiretroviral therapy

AIDS Patient Care and STDs

Volumn 14, Issue 11, 2000, Pages 595-601

  Ridolfo, A L ^a   Gervasoni, C ^a   Bini, T ^a   Galli, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CORTICOTROPIN; DIDANOSINE; GROWTH HORMONE; HYDROCORTISONE; LAMIVUDINE; LIPOPROTEIN RECEPTOR; PROLACTIN; PROTEINASE INHIBITOR; RETINOIC ACID BINDING PROTEIN; STAVUDINE; TESTOSTERONE; ZIDOVUDINE;

ARTICLE; BODY FAT; FAT INTAKE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIPIDOSIS; PATHOGENESIS; PHENOTYPE; PROTEINASE INHIBITION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; BODY COMPOSITION; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MIDDLE AGED; OBESITY; REVERSE TRANSCRIPTASE INHIBITORS; TRIGLYCERIDES; VIRAL LOAD;

EID: 0033767682     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/10872910050193770     Document Type: Article

References (34)

1. Fat distribution and metabolic changes in patients with HIV infection
2. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
3. Indinavir-associated lipodystrophy
4. Abnormal fat distribution and use of protease inhibitors
5. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
6. Hypertrophy of the breast in a patient treated with indinavir
7. Another case of breast hypertrophy in a patient treated with indinavir
8. 'Buffalo hump' in men with HIV-1 infection
9. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors
10. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients
11. Visceral abdominal-fat accumulation associated with use of indinavir
12. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART)
13. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
14. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
15. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
16. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy
17. Protease inhibitors and nucleoside analogue reverse transcriptase inhibitors interact to cause subcutaneous fat wasting in patients with HIV infection
18. Prevalence of fat deposition and fat atrophy in a cohort of HIV-infected men and women
19. Body habitus assessment in HIV-infected women: A cross-sectional study
20. Gender differences in HIV-associated adipose redistribution syndrome (HARS): An update
21. Gender differences in prevalence of body habitus changes and metabolic complications in HIV+ African American and Latino individuals from Harlem
22. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
23. Lipodystrophy in patients naive to HIV protease inhibitors
24. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
25. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome
26. Cortisol resistance in acquired immunodeficiency syndrome
27. The HIV-1 virion-associated protein Vpr is a coactivator of the human glucocorticoid receptor
28. Differential inhibition of cytocrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
29. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
30. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
31. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy
32. Incidence of fat tissue abnormalities in protease inhibitor-naive patients treated with NRTI combinations
33. Cumulative time-dependent probability of developing fat tissue alterations in female patients treated with combined antiretroviral therapy